Full-Time
Senior Market Access Analyst 2
Glaukos
1,001-5,000 employees
Medical devices for glaucoma treatment
Compensation Overview
$130.3k - $162.9k/yr
Aliso Viejo, CA, USA
Remote
Bachelor's, Master's, PhD
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Glaukos
See people who can refer or advise you
- Bachelor's degree required; advanced degree preferred
- 8+ years of experience in market access analytics, pricing, reimbursement, HEOR, or related healthcare analytics functions
- Deep understanding of payer dynamics, reimbursement, and channel strategy
- Experience influencing senior leaders through data-driven recommendations
- Strong analytical, modeling, and problem-solving skills
- Proven ability to build and scale analytics capabilities that drive business impact
- Lead enterprise-wide market access analytics across pricing, contracting, reimbursement, and channel strategy
- Develop scenario models and business impact assessments to support strategic decision-making
- Provide executive-level insights on access performance, risks, and opportunities
- Define and track key performance indicators related to payer access, reimbursement, and patient journey performance
- Lead analytics supporting Buy and Bill and Specialty Pharmacy channel optimization
- Analyze HUB, payer, and field reimbursement data to identify trends and access barriers
- Build scalable reporting, analytics, and data governance capabilities across multiple data sources
- Partner cross-functionally with Commercial, Market Access, Finance, Patient Services, and other stakeholders to support strategic planning and business growth
Glaukos focuses on ophthalmology by developing and commercializing medical devices and therapies for glaucoma, corneal disorders, and retinal diseases. Its products mainly target surgeons who treat eye conditions, with a core technology in micro invasive glaucoma surgery (MIGS). The company’s MIGS devices, such as the Trabecular Micro Bypass Stent and next-generation iStent, are implanted in the eye to improve outflow of eye fluid and lower intraocular pressure, offering a less invasive option compared with traditional surgeries. Glaukos differentiates itself by pioneering MIGS and bringing the first US-approved MIGS device to market in 2012, continuing to expand its portfolio through research, development, and strategic acquisitions. The company aims to improve patient care by providing safer, effective, and longer-lasting treatment options for glaucoma and related eye diseases, addressing unmet needs in ophthalmology.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Aliso Viejo, California
Founded
1998
Get referred to Glaukos
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $185.6 million, up 50%, and guidance rose to $680-$700 million.
- Epioxa's permanent J2789 code became effective July 1, 2026, improving reimbursement access.
- Preserflo enrollment finished July 27, 2026, extending Glaukos into advanced glaucoma surgery.
What critics are saying
- Five Medicare MACs proposed iDose TR LCDs in Q2 2026, threatening coverage by year-end.
- Epioxa faces third-quarter volatility while physicians and payers shift from Photrexa and temporary coding.
- German and Swiss reimbursement headwinds, plus competitive trialing, pressure international glaucoma growth in 2026.
What makes Glaukos unique
- Glaukos pioneered MIGS and still owns iStent, iStent inject W, and iStent infinite.
- iDose TR delivered $74 million of Q2 2026 U.S. glaucoma sales.
- Epioxa is the first FDA-approved epithelium-on keratoconus therapy, now supported by J2789.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 0%Glaukos reported record second-quarter revenue of $185.6 million, up 50% year over year, driven by strong performance in US glaucoma, international glaucoma and corneal health. The company raised its full-year sales guidance to $680 million–$700 million, up from the prior range of $620 million–$635 million. US glaucoma franchise revenue reached $118.5 million, increasing 64% year over year, with iDose TR contributing approximately $74 million. Glaukos expects iDose TR revenue of roughly $275 million–$280 million in 2026. Corneal health revenue increased 48% to $30.4 million, supported by the Epioxa launch. Gross margin reached approximately 85% as management continues investing in commercialisation and its pipeline whilst targeting cash-flow breakeven.
Glaukos Q2 earnings call highlights. July 29, 2026 Key points. * Record Q2 sales: Glaukos reported $185.6 million in second-quarter revenue, up 50% year over year, driven by strong U.S. glaucoma, international glaucoma and corneal health performance. The company raised its 2026 sales guidance to $680 million-$700 million. * iDose TR led growth: U.S. glaucoma revenue rose 64% to $118.5 million, including approximately $74 million from iDose TR. Glaukos expects iDose TR revenue of roughly $275 million-$280 million in 2026, while Medicare coverage proposals remain under review. * Corneal health and profitability gains: Corneal health revenue increased 48% to $30.4 million, supported by the Epioxa launch, though third-quarter results may be volatile during the transition to its permanent billing code. Gross margin reached about 85%, and management continues investing in commercialization and its pipeline while targeting cash-flow breakeven. * MarketBeat previews top five stocks to own in August. Glaukos NYSE: GKOS reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth in its U.S. glaucoma, international glaucoma and corneal health businesses exceeded management's expectations. Chairman and CEO Tom Burns said the company raised its full-year net sales guidance to $680 million to $700 million, up from its prior range of $620 million to $635 million. The company cited continued adoption of iDose TR, the launch of Epioxa, and broad-based international growth as drivers of the stronger outlook. iDose TR drives U.S. Glaucoma growth. U.S. glaucoma franchise revenue reached a record $118.5 million in the second quarter, increasing 64% year over year. iDose TR contributed approximately $74 million of that total. Burns said physician interest and adoption of iDose TR continued to grow, supported by its clinical outcomes and what the company views as a shift toward earlier interventional glaucoma care. Glaukos is focused on adding trained surgeons and active accounts, increasing utilization, expanding market access, and growing clinical evidence for the treatment. President and COO Joe Gilliam said Glaukos now expects U.S. glaucoma revenue to grow about 50%, plus or minus, for the full year. The company expects its broader U.S. glaucoma portfolio to post at least low-single-digit growth, while iDose TR revenue is expected to land in a range of roughly $275 million to $280 million in 2026. Gilliam said the second-quarter iDose performance reflected acceleration across Medicare Administrative Contractor regions as well as increased activity among commercial and Medicare Advantage patients. He said the company did not identify material demand pull-forward related to proposed Medicare local coverage determinations, or LCDs. Five of seven Medicare Administrative Contractors issued proposed LCDs for iDose TR during the quarter. Gilliam said Glaukos was encouraged by support from physicians, medical societies and patients during public meetings and comment periods. He said the company believes the evidence supporting iDose TR should lead to a more favorable final policy if LCDs are finalized. Earlier in July, CMS issued proposed 2027 rules that, as drafted, largely maintain 2026 ambulatory payment classifications, facility payments and relative physician fee rates for Glaukos procedures in hospital outpatient and ambulatory surgical center settings, Burns said. International and corneal health performance. International glaucoma revenue was $36.6 million, up 17% reported and 16% on a constant-currency basis. Gilliam said Glaukos now expects low- to mid-teens international glaucoma growth for the full year. Discover more Stock Ratings Screener Management expects foreign-exchange tailwinds to diminish in the second half. The company also cited competitive product trialing and reimbursement headwinds in Germany and Switzerland, though it expects those factors to be partly offset by growth from PRESERFLO and iStent infinite. Corneal health revenue rose 48% to $30.4 million, including about $11 million in Epioxa sales. Epioxa is the company's FDA-approved epithelium-on corneal cross-linking therapy for keratoconus. Gilliam said Glaukos now expects the overall corneal health franchise to grow approximately 20%, plus or minus, in 2026. He cautioned that third-quarter performance could be volatile as the company transitions from Photrexa and a miscellaneous billing code to Epioxa's permanent product-specific J-code, which became effective July 1. "There will be some volatility" during the transition, Gilliam said, though he expects the related issues to begin moving behind the company in the fourth quarter. * O2n systems are deployed at locations serving roughly 85% of the U.S. population, with a pipeline that Glaukos expects could extend reach to approximately 95%. * Access pathways for Epioxa have been established for more than 125 million covered commercial lives, including arrangements involving the five largest U.S. payers. * Glaukos launched a co-pay assistance program for eligible patients and is investing in awareness, referral networks, earlier diagnosis and patient-support programs. Gilliam said the company has been encouraged by the number of patients being submitted for Epioxa approval, though providers and payers are adjusting to the new permanent J-code. He said some institutions and larger groups are more comfortable using a buy-and-bill model, while many community practices are initially relying more heavily on specialty pharmacy distribution. Pipeline and profitability focus. Glaukos said it continues to advance programs across five therapeutic platforms. Its pipeline includes iDose TREX, which is in a Phase II-B/III program; iDose Trio, with a Phase III-B study targeting FDA approval by the end of 2027; and a planned commercial introduction later this year of a keratoconus screening device. The company also said it is preparing a Phase III program for a third-generation customized topographically guided iLink therapy in 2027. In other programs, Glaukos completed enrollment in a 510(k) pivotal study for PRESERFLO MicroShunt and in a Phase II study for demodex blepharitis, with top-line results from the latter expected by year-end. The company is also advancing a first-in-human study of GLK-401 for wet age-related macular degeneration. Chief Financial Officer Alex Thurman said the company was pleased with second-quarter progress across gross margin, operating expenses, the bottom line and cash generation. Gross margin was approximately 85% in the quarter, up about 90 basis points sequentially, driven by a greater revenue contribution from iDose TR and Epioxa. Glaukos maintained its full-year gross-margin target of 84% to 86% and expects modest additional accretion through the remainder of 2026, particularly in the fourth quarter. Thurman said operating expenses are now expected to total around $600 million for the year. While management sees a clearer path toward profitability as revenue grows, Thurman said Glaukos intends to continue investing in commercialization and clinical development to support its product launches and pipeline, while managing the business toward cash-flow breakeven. About Glaukos (NYSE:GKOS). Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure. Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Glaukos, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list. While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.
Glaukos completes enrollment for glaucoma implant study. To support FDA submission Yuika Yoshida July 27, 2026 Glaukos Corp. today announced it has completed enrollment for a 510(k) study of an implantable drainage device designed to lower eye pressure in glaucoma patients. The study enrolled 110 adult patients with primary open-angle glaucoma who failed previous medical and surgical treatment. Results from the study will support a future FDA marketing submission. The device, dubbed Preserflo MicroShunt, is currently approved and commercially available in Canada and Australia. Shares in Glaukos were down 1.3% to $151.63 apiece and an $8.9 billion market cap (NYSE: GKOS). Want more from the best local business newspaper in the country? Sign-up for its FREE Daily eNews update to get the latest Orange County news delivered right to your inbox! One-Year for Only $99 * Weekly in-depth coverage in print and digital formats * Special Features: OC's Wealthiest, Top Priced Home Sales, Giving Guide, OC500, Charity Event Guide, Best Places to Work, Indispensables, Largest Charitable Gifts * The annual Book of Lists: Orange County's top companies across every industry
Glaukos completes enrollment in US pivotal study of Preserflo MicroShunt for POAG. Key Takeaways * Glaukos has completed enrollment in its US 510(k) pivotal study evaluating the Preserflo MicroShunt in adults with refractory primary open-angle glaucoma * The study will assess whether the device achieves a 20% or greater reduction in mean diurnal IOP at 12 months without increasing the number of glaucoma medication classes * Positive study results are expected to support a future FDA marketing submission Glaukos has completed patient enrollment in its US 510(k) pivotal clinical study evaluating the Preserflo MicroShunt in adults with primary open-angle glaucoma (POAG) whose disease remains inadequately controlled despite previous medical and surgical treatment. The milestone advances the company's effort to seek US regulatory clearance for the glaucoma drainage device, which is designed to reduce IOP through a minimally invasive, ab-externo surgical approach. According to the company, the Preserflo MicroShunt is an 8.5-mm flexible drainage device constructed from SIBS (poly(styrene-block-isobutylene-block-styrene)), a proprietary biocompatible material. The device incorporates planar fins intended to promote tissue fixation, maintain implant positioning, and minimize leakage following implantation. "The completion of patient enrollment in our US pivotal study represents an important milestone toward potentially bringing the Preserflo MicroShunt to US patients with advanced glaucoma who are at risk for significant vision loss," said Thomas Burns, chairman and chief executive officer of Glaukos. Mr. Burns added that the company believes the device could address an unmet clinical need by providing glaucoma specialists with an ab-externo surgical alternative to conventional filtration procedures such as trabeculectomy and tube shunt surgery. He also said the company remains focused on expanding its glaucoma portfolio as the study progresses through patient follow-up. The prospective, multicenter, single-arm trial enrolled at least 110 patients across sites in the United States and Canada. Eligible participants had previously undergone unsuccessful incisional or cilioablative glaucoma surgery and continued to have inadequately controlled IOP despite treatment with IOP-lowering medications. The study's primary effectiveness endpoint is achieving at least a 20% reduction in mean diurnal IOP from baseline at 12 months after surgery without an increase in the number of IOP-lowering medication classes compared with baseline. Glaukos plans to use the study findings to support a future FDA marketing submission for the device. Glaukos holds exclusive rights to develop and commercialize the Preserflo MicroShunt in the United States, Australia, New Zealand, Canada, Brazil, and Mexico under a licensing agreement with Santen. The device is already approved and commercially available in several international markets, including Canada and Australia, where the company said surgeon adoption continues to increase alongside growing real-world evidence supporting its safety and effectiveness.
Glaukos announces completion of patient enrollment in 510(k) pivotal study for PRESERFLO(TM) MicroShunt. July 27, 2026 ALISO VIEJO, Calif.-(BUSINESS WIRE)- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the completion of patient enrollment in its U.S. 510(k) pivotal study evaluating the PRESERFLO(TM) MicroShunt in adult patients with primary open-angle glaucoma (POAG) who failed previous medical and surgical treatment. The PRESERFLO MicroShunt is a novel, ab-externo glaucoma drainage device designed to lower intraocular pressure (IOP). Constructed from a proprietary, biocompatible material known as SIBS [poly(styrene-block-isobutylene-block-styrene)], the PRESERFLO MicroShunt is an 8.5 mm flexible drainage device featuring planar fins designed to facilitate tissue fixation through a minimally-invasive procedure while helping maintain device positioning and minimize leakage. "The completion of patient enrollment in our U.S. pivotal study represents an important milestone toward potentially bringing the PRESERFLO MicroShunt to U.S. patients with advanced glaucoma who are at risk for significant vision loss," said Thomas Burns, Glaukos chairman and chief executive officer. "We believe the PRESERFLO MicroShunt has the potential to address an important unmet clinical need by providing glaucoma specialists with an elegant, ab-externo surgical alternative to conventional filtration procedures such as trabeculectomy and tube shunt surgery. As we advance into the next phase of this clinical program through patient follow-up, we remain committed to expanding our comprehensive, best-in-class portfolio of novel glaucoma therapies designed to address the evolving needs of patients and physicians across the full continuum of glaucoma care." The PRESERFLO MicroShunt prospective, multi-center, single-arm clinical trial enrolled patients who had previously undergone unsuccessful incisional or cilioablative glaucoma surgery and whose IOP remained inadequately controlled with IOP-lowering medications. The study successfully enrolled its target of at least 110 patients across clinical sites in the United States and Canada. The study's primary effectiveness endpoint is a 20% or greater reduction in mean diurnal IOP from baseline at 12 months postoperatively without an increase in the number of IOP-lowering medication classes from baseline. Glaukos intends to use the study results to support a future FDA marketing submission for the PRESERFLO MicroShunt. Glaukos holds the exclusive rights to develop and commercialize the PRESERFLO MicroShunt in the United States, Australia, New Zealand, Canada, Brazil, and Mexico under its license agreement with Santen Pharmaceutical Co., Ltd. The device is currently approved and commercialized in several of these markets, including Canada and Australia, where surgeon adoption continues to grow alongside an expanding body of favorable real-world evidence supporting the device's safety and effectiveness. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose(R) TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases. Forward-Looking Statements All statements other than statements of historical facts included in this press release that address activities, events or developments that Glaukos Corporation expect, believe or anticipate will or may occur in the future are forward-looking statements. Although Glaukos Corporation believe that Glaukos Corporation has a reasonable basis for forward-looking statements contained herein, Glaukos Corporation caution you that they are based on current expectations about future events affecting Glaukos Corporation and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control, that may cause its actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the timing and extent to which Glaukos Corporation obtain regulatory approval for investigational products such as the PRESERFLO MicroShunt, its ability to successfully commercialize such products, the ability to obtain and maintain adequate financial coverage and reimbursement for its products, and the continued efficacy and safety profile of its products. These and other risks, uncertainties and factors related to Glaukos, and its business are described in detail under the caption "Risk Factors" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 23, 2026, along with Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which was filed with the SEC on April 30, 2026. Its filings with the SEC are available in the Investor Section of its website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of its products is available on its website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. Glaukos Corporation do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law. Investor Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs [email protected]